Antibodies for bioanalysis and drug monitoring of ipilimumab

Develop highly selective and sensitive PK and ADA assays for the immune checkpoint inhibitor drug ipilimumab (Yervoy) using our range of ready-made anti-idiotypic antibodies.

  • Highly specific to ipilimumab or the ipilimumab-CTLA-4 complex
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Ipilimumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Ipilimumab Inhibitory

Type 1

HCA330

AbD34433

Fab-FSx21

0.3

PK bridging ELISA

Order HCA330

HCA329
HCA329P

AbD34429ia

Human IgG1

HRP

1

PK bridging ELISA

ADA control

Order HCA329
Order HCA329P

HCA327

AbD34283ia

Human IgG1

16

ADA control

Order HCA327

HCA328

AbD34428ia

Human IgG1

0.3

ADA control

Order HCA328

Ipilimumab-CTLA-4 Complex Specific

Type 3

HCA331

AbD34294

Fab-FSx21

252

PK ELISA antigen capture format

Order HCA331

* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK and StrepX-StrepX-tags

Anti-Ipilimumab Inhibitory Antibodies (Type 1)

Type 1 anti-ipilimumab antibodies inhibit the binding of the drug ipilimumab to its target, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in a three different affinities, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

Anti-Ipilimumab-CTLA-4 Complex Specific Antibody (Type 3)

The Type 3 antibody specifically recognizes the drug-target complex, detecting ipilimumab only when it is bound to CTLA-4. It is suitable as a detection antibody in a PK antigen capture assay, as an alternative assay format to the bridging ELISA.

ELISA Protocols to Get You Started

PK Bridging ELISA

PK bridging ELISA: HCA330 (capture) and HCA329P (detection)

Fig. 1. Ipilimumab PK bridging ELISA using antibodies HCA330 and HCA329P.

Fig. 1. Ipilimumab PK bridging ELISA using antibodies HCA330 and HCA329P.

Schematic image of PK bridging ELISA measuring free drug

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

PK Antigen Capture ELISA

PK antigen capture ELISA: CTLA-4 (capture) and HCA331 (detection)

Fig. 2. Ipilimumab PK antigen capture ELISA using antibody HCA331.

Fig. 2. Ipilimumab PK antigen capture ELISA using antibody HCA331.

Schematic image of PK antigen capture ELISA

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), anti-tag detection antibody labeled with HRP (gray).

ADA Bridging ELISA

ADA bridging ELISA: HCA327, HCA328, HCA329 fully human IgG1 as surrogate positive control or calibrator

Fig. 3. Ipilimumab ADA bridging ELISA using antibody HCA327, HCA328 or HCA329.

Fig. 3. Ipilimumab ADA bridging ELISA using antibody HCA327, HCA328 or HCA329.

Schematic image of ADA bridging assay

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Related Product

Ipilimumab drug isotype control Recombinant Human IgG1 Kappa (HCA192)

Resources

Anti-idiotypic antibodies, their binding types and properties

Anti-biotherapeutic antibody quality control and characterization

Custom anti-idiotypic antibody generation service

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.